The EPA (Environmental Protection Agency) has recently registered a new product for preventing and eliminating methicillin-resistant Staphylococcus aureus (MRSA), which causes potentially deadly infections commonly known as “staph” infections. The MRSA “super bug” is typically contracted in hospitals, in other healthcare environments, and in health clubs and locker rooms.
The EPA has registered Selectrocide chlorine dioxide for use as a disinfectant on hard, non-porous surfaces and instruments, including those used within hospitals and other medical settings. As a no-wipe, no-rinse spray, Selectrocide chlorine dioxide can also be used on hard, non-porous surfaces in health clubs, spas, public places and swimming facilities as a treatment against MRSA. The EPA has also registered Selectrocide as a disinfectant for vancomycin-resistant Enterococcus faecalis, athlete’s foot, Mycobacterium bovis (TB) and other pathogens that spread in many environments.
MRSA is usually spread by direct physical contact with those already infected or through indirect contact by touching objects (towels, clothes, sports equipment, etc.) that infected skin has contaminated. Consequently, any heavily trafficked area can be a source of infection.
According to a report by the BBC News, “Staphylococcus aureus is the leading cause of human infections in the skin and soft tissues, bones and joints, abscesses and normal heart valves. It flourishes in the hospital setting, producing bloodstream and surgical wound infections, including MRSA.” (news.bbc.co.uk/1/hi/health/4671585.stm)